Compare DCO & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCO | GLUE |
|---|---|---|
| Founded | 1849 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | DCO | GLUE |
|---|---|---|
| Price | $115.39 | $23.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $128.40 | $29.50 |
| AVG Volume (30 Days) | 132.4K | ★ 2.5M |
| Earning Date | 02-26-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $806,224,000.00 | $181,538,000.00 |
| Revenue This Year | $6.11 | $84.02 |
| Revenue Next Year | $8.03 | N/A |
| P/E Ratio | ★ N/A | $95.99 |
| Revenue Growth | 3.17 | ★ 1112.27 |
| 52 Week Low | $51.76 | $3.50 |
| 52 Week High | $115.34 | $25.77 |
| Indicator | DCO | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 78.10 | 62.69 |
| Support Level | $111.30 | $23.01 |
| Resistance Level | $115.34 | $24.57 |
| Average True Range (ATR) | 3.28 | 1.72 |
| MACD | 0.99 | 0.18 |
| Stochastic Oscillator | 92.27 | 79.06 |
Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.